

Tania Jain

List of Publications by Citations

Source: <https://exaly.com/author-pdf/887518/tania-jain-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

906
citations

18
h-index

27
g-index

123
ext. papers

1,431
ext. citations

3.8
avg, IF

4.53
L-index

#	Paper	IF	Citations
98	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2305-2321	4.7	68
97	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020 , 4, 3776-3787	7.8	59
96	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6656-6667	15.9	55
95	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020 , 4, 676-686	7.8	51
94	Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 157-63	4.7	48
93	Levamisole-induced leukocytoclastic vasculitis and neutropenia in a patient with cocaine use: an extensive case with necrosis of skin, soft tissue, and cartilage. <i>Addiction Science & Clinical Practice</i> , 2012 , 7, 19	4.1	39
92	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. <i>Blood Advances</i> , 2018 , 2, 3393-3403	7.8	34
91	Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. <i>American Journal of Transplantation</i> , 2020 , 20, 2254-2259	8.7	33
90	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1071-1076	4.7	32
89	Schnitzler syndrome: an under-diagnosed clinical entity. <i>Haematologica</i> , 2013 , 98, 1581-5	6.6	28
88	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 204-211	4.4	27
87	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 1965-1973	7.8	23
86	Bronchoscopy can be done safely in patients with thrombocytopenia. <i>Transfusion</i> , 2016 , 56, 344-8	2.9	22
85	Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. <i>Leukemia Research</i> , 2017 , 54, 73-77	2.7	21
84	Allogeneic Stem Cell Transplantation in Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1429-1436	4.7	20
83	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019 , 33, 2540-2544	10.7	20
82	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 239-247	4.7	19

81	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. <i>Annals of Hematology</i> , 2018 , 97, 1453-1462	3	18
80	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620719899897	5.7	16
79	Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 728-733	4.7	16
78	Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2017 , 7, 642	7	14
77	Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. <i>Annals of Hematology</i> , 2016 , 95, 1323-7	3	13
76	Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa598	1	13
75	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 25-34	3.1	13
74	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.. <i>Nature Medicine</i> , 2022 ,	50.5	13
73	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 6-20		12
72	Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. <i>BMJ Supportive and Palliative Care</i> , 2019 , 9, 425-433	2.2	11
71	BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 531-5	2	11
70	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1248-1269	7.3	10
69	The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 1101-1108	3.5	7
68	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021 , 5, 3397-3406	7.8	7
67	HHV-8-Associated Lymphoproliferative Disorders and Pathogenesis in an HIV-Positive Patient. <i>Case Reports in Hematology</i> , 2019 , 2019, 4536157	0.7	6
66	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020 , 10, 36	7	6
65	Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018 , 93, 1220-1226	7.1	6
64	Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma. <i>Cureus</i> , 2015 , 7, e410	1.2	6

63	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020 , 4, 5078-5088	7.8	6
62	Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. <i>British Journal of Haematology</i> , 2021 , 195, 660-668	4.5	6
61	Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1996-2002	1.9	6
60	Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, E504-E505	7.1	5
59	Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 110-117	1.9	5
58	Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. <i>British Journal of Haematology</i> , 2021 , 193, 1142-1150	4.5	5
57	Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 398-402	4.7	5
56	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
55	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 642-649		4
54	Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. <i>Leukemia</i> , 2020 , 34, 3060-3063	10.7	3
53	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 486-492.e1	2	3
52	Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. <i>Journal of Clinical Apheresis</i> , 2014 , 29, 293-8	3.2	3
51	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020 , 136, 33-34	2.2	3
50	Prospective Evaluation Of Risk Factors For Clostridium Difficile Colonization Among Allogeneic Hematopoietic Stem Cell Transplant Recipients, 2010-2012. <i>Blood</i> , 2013 , 122, 4563-4563	2.2	3
49	Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2126-2126	2.2	3
48	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics.. <i>Transplantation Direct</i> , 2022 , 8, e1268	2.3	3
47	Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, S279-S280	4.7	2
46	Cytomegalovirus Reactivation Promotes CD8+ T Cell Subset Recovery after Unmodified Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, S326-S327	4.7	2

45	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. <i>Hematological Oncology</i> , 2020 , 38, 654-664	1.3	2
44	High Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, S48	4.7	2
43	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2019 , 134, 1947-1947	2.2	2
42	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. <i>Blood</i> , 2015 , 126, 1361-1361	2.2	2
41	Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience. <i>Blood</i> , 2015 , 126, 2818-2818	2.2	2
40	CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. <i>EJHaem</i> , 3 , 32	0.9	2
39	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. <i>Blood</i> , 2017 , 130, 864-864	2.2	2
38	Accelerated and Blast Phase Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 325-335	3.1	2
37	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <i>Anti-Cancer Drugs</i> , 2019 , 30, 859-865	2.4	2
36	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 921.e1-921.e10		2
35	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.. <i>Leukemia and Lymphoma</i> , 2022 , 1-7	1.9	2
34	Bone Disease in Myeloma: The Claws of CRAB. <i>Clinical Cancer Research</i> , 2016 , 22, 1301-3	12.9	1
33	Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 192-192	2.2	1
32	An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019 , 8, e11591	2	1
31	Characteristics of colorectal cancer in patients younger than 40 years compared to older patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 371-371	2.2	1
30	Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
29	Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms. <i>EJHaem</i> , 2021 , 2, 607-615	0.9	1
28	Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?. <i>Leukemia and Lymphoma</i> , 2021 , 62, 252-254	1.9	1

27	American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy.. <i>Transplantation and Cellular Therapy</i> , 2021 ,		1
26	Immunophenotypic and molecular analysis of a B cell lymphoma with discordant light chain expression at different anatomic sites. <i>Journal of Hematopathology</i> , 2020 , 13, 117-123	0.4	0
25	The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. <i>Blood</i> , 2021 , 138, 253-253	2.2	0
24	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 909.e1-909.e6		0
23	Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use. <i>Blood</i> , 2020 , 136, 44-45	2.2	
22	Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL. <i>Blood</i> , 2020 , 136, 42-44	2.2	
21	Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). <i>Blood</i> , 2020 , 136, 40-40	2.2	
20	Insights into the Pathobiology of Secondary AML. <i>Hematologic Malignancies</i> , 2021 , 57-68		0
19	The Presence of SETBP1, RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents. <i>Blood</i> , 2021 , 138, 1520-1520	2.2	
18	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021 , 138, 1846-1846	2.2	
17	The effect of neutropenic diets on infection and mortality rates in cancer patients: An updated systematic review and meta- analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22087-e22087	2.2	
16	Rituximab maintenance for mantle cell lymphoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e19557-e19557	2.2	
15	Choosing a reduced intensity conditioning, fludarabine melphalan versus fludarabine busulfan: A meta-analysis and systematic review.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e19017-e19017	2.2	
14	Does Early T Cell Chimerism Predict Outcomes after Allogeneic Hematopoietic Cell Transplantation ?. <i>Blood</i> , 2018 , 132, 3360-3360	2.2	
13	Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score. <i>Blood</i> , 2018 , 132, 4288-4288	2.2	
12	Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMiDs) Sensitivity in Myeloma. <i>Blood</i> , 2018 , 132, 4443-4443	2.2	
11	Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG. <i>Blood</i> , 2018 , 132, 5715-5715	2.2	
10	Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T). <i>Blood</i> , 2019 , 134, 4455-4455	2.2	

- 9 Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. *Blood*, **2019**, 134, 4458-4458 2.2
- 8 Severe Thrombocytopenia Does Not Increase Bleeding Complications in Patients Undergoing Bronchoscopy. *Blood*, **2014**, 124, 4293-4293 2.2
- 7 Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. *Blood*, **2016**, 128, 4653-4653 2.2
- 6 Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. *Blood*, **2016**, 128, 1810-1810 2.2
- 5 Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. *Blood*, **2016**, 128, 3452-3452 2.2
- 4 Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL). *Blood*, **2016**, 128, 4629-4629 2.2
- 3 Successful Hematopoietic Stem Cells (HSC) Mobilization in Patients Who Fail Plerixafor Mobilization for Autologous Stem Cells Transplant (ASCT). *Blood*, **2012**, 120, 1913-1913 2.2
- 2 Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2020**, 26, e263-e264 4-7
- 1 Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?. *Leukemia and Lymphoma*, **2019**, 60, 2034-2041 1.9